April 17th Options Now Available For Cameco (CCJ)

Stock Options Channel outlines two option strategies on Cameco Corp. (CCJ, $112.59): selling a $110 put (bid $9.50) would obligate purchase at $110 with an effective cost basis of $100.50 and is estimated to have a 60% chance of expiring worthless, yielding 8.64% (45.06% annualized). Alternatively, selling a $115 covered call (bid $10.70) against shares purchased at $112.59 would cap sale at $115 for a potential total return of 11.64% to April 17 expiry, with a 47% probability of expiring worthless and a 9.50% yield boost (49.58% annualized); implied vol is ~62% vs. trailing 12-month volatility of 52%.

Analysis

Market structure: Option sellers and income-focused accounts are the immediate beneficiaries — sellers can pocket ~9–11% gross to Apr 17 (110 put @9.50, 115 call @10.70) while prospective buyers get an effective entry at $100.50 if assigned. Elevated implied vol (~62%) vs realized (~52%) signals options are relatively expensive, creating opportunities to sell premium but also increasing gamma/pinning risk into the 110–115 band into expiry. Broader winners: uranium producers and ETFs (e.g., CCJ, URA) if utility contracting picks up; losers include cyclical miners without uranium exposure if capital rotates into niche nuclear plays.

Risk assessment: Tail risks include sudden regulatory reversals (e.g., nuclear policy shifts), operational mine disruptions, or a sharp drop in global electricity demand — each could wipe 20–40% off CCJ in a stress scenario. Short-term (days-weeks) risks are option pinning and IV compression around Apr 17; medium-term (1–3 months) risks are spot uranium moves or contract-roll news; long-term (quarters+) depend on secular utility contracting and geopolitical supply (Russia/France). Hidden dependencies: Cameco’s cash flows are sensitive to long-term utility contract cadence and geopolitical supply shocks that are not priced into short-dated options.

Trade implications: Primary tactical play is selling cash-secured 110 puts (Apr 17) sized so max assignment equals desired exposure — effective cost $100.50; probability of expiry worthless ~60% per current analytics. For existing holders, selling Apr 17 115 covered calls yields ~11.6% to expiry; consider rolling only if underlying >+6% approaching expiry. If selling premium, prefer defined-risk structures (bull-put spreads: sell 110/buy 95) to cap tail loss while capturing elevated IV.

Contrarian angles: Consensus leans toward short-dated income trades and underestimates secular upside from utility contracting; if long-term uranium demand materializes, being assigned at $100.50 could be a gift. Conversely, IV looks rich vs realized — premium selling is attractive but can be fatally wrong if a regulatory/operational shock occurs; historical uranium cycles (2006 peak then crash) warn against large uncovered short-vol positions. Unintended consequence: heavy put-selling could mechanically support the 110 level, creating a crowded short-vol squeeze if spot spikes.

Key Decisions for Investors

• If comfortable owning CCJ, sell-to-open 1–3 cash‑secured 110 puts (Apr 17) per $10k notional exposure — collect $9.50/contract -> effective basis $100.50; cap sizing so assigned shares represent no more than 2% of portfolio and reserve capital for margin.
• Existing CCJ holders: sell Apr 17 115 covered calls (collect $10.70) for ~11.6% gross to expiry; if CCJ trades >+6% within 7 days of expiry, roll to May 120 calls only if you want to retain shares and can collect ≥50% of original premium.
• Prefer defined-risk premium-selling: construct a bull-put spread (sell 110/ buy 95 Apr 17) to convert naked put sale into limited-risk trade; target net credit ≥$7.00 per share (implied max loss ~ $15 - credit) and limit notional to 1–2% portfolio.
• Do not short naked calls or straddles. Monitor these triggers for position adjustments: U3O8 spot move ±10% over 30 days, Cameco quarterly release, or any US/Canada/IAEA regulatory announcement — act within 48 hours to hedge or trim if triggers hit.